AA
ENZ

ALPS Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History

ALPS Advisors’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-39,771
Closed -$324K – 1008
2017
Q4 		$324K Sell
39,771
-3,000
-7% -$28.7K ﹤0.01% 726
2017
Q3 		$448K Buy
+42,771
New +$475K ﹤0.01% 669

Other funds holding ENZ

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ALPS Advisors's ENZ Position: Q1 2018 in Review

ALPS Advisors sold out of Enzo Biochem, Inc. (ENZ) in Q1 2018, closing a stake of 39,771 shares — an estimated $324K sold.

ALPS Advisors first reported a position in ENZ in Q3 2017 and held it in 2 quarters. The position peaked at $448K in Q3 2017. 107 funds tracked by Wall St. Rank hold ENZ as of Q1 2018.

  • ALPS Advisors reported no remaining Enzo Biochem, Inc. position as of Q1 2018 after selling out during the quarter.
  • ALPS Advisors sold 39,771 Enzo Biochem, Inc. shares in Q1 2018, an estimated $324K.
  • ALPS Advisors first reported a position in Enzo Biochem, Inc. in Q3 2017 and held it in 2 quarters.
  • ALPS Advisors's Enzo Biochem, Inc. position peaked at $448K in Q3 2017.
  • 107 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2018.

Based on ALPS Advisors's 13F filing for Q1 2018, filed 1 May 2018.